February 29, 2024 01:40 PM ESTUpdated 06:00 PM
Pharma
Law

San­doz pays out $265M to set­tle part of an­titrust law­suit

Katherine Lewin

News Reporter

San­doz and its sub­sidiary Fougera Phar­ma­ceu­ti­cals have agreed to shell out $265 mil­lion in an an­titrust case brought against them in Penn­syl­va­nia’s east­ern dis­trict. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times